Monoclonal protein and peripheral neuropathy

doi:10.3969/j.issn.1006-7795.2018.03.007

Abstract

CLC Number:

R741

Hao Yuanyuan, Sun Wanling. Monoclonal protein and peripheral neuropathy[J]. Journal of Capital Medical University, 2018, 39(3): 344-348.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.03.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I3/344

[1] Katz J S, Saperstein D S, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy[J]. Neurology, 2000,83(3):615-620.
[2] Filosto M, Cotelli M, Todeschini A, et al. Clinical spectrum and evolution of monoclonal gammopathy-associated neuropathy[J]. Neurologist,2012,18(6):378-384.
[3] Nobile-Orazio E. Hand book of clinical neurology[M]. Netherlands:Elsevier, 2013:443-459.
[4] Larue S, Bombelli F, Viala K, et al. Non-anti-MAG DADS neuropathy as a variant of CIDP:clinical, electrophysiological, laboratory features and response to treatment in 10 cases[J]. Eur J Neurol, 2011,18(6):899-905.
[5] Svahn J, Petiot P, Antoine J, et al. Anti-MAG antibodies in 202 patients:clinicopathological and therapeutic features[J]. J Neurol Neurosurg Psychiatry, 2018,89(5):499-505.
[6] Kawagashira Y, Koike H, Ohyama K, et al. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody[J]. J Neurol Sci, 2015,348(1-2):67-73.
[7] Larsen L H, Lund T, Vilholm O J, et al. Anti-myelin associated glycoprotein neuropathy responding to lenalidomide[J]. Leuk Res, 2011,35(11):e198-e199.
[8] Stino A M, Efebera Y. Lenalidomide-responsive antimyelin-associated glycoprotein neuropathy[J]. Muscle Nerve, 2017,56(4):E31-E32.
[9] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2017年修订)[J]. 中华内科杂志, 2017,56(11):866-870.
[10] D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma):a single-center experience[J]. Blood, 2012,120(1):56-62.
[11] Muchtar E, Gertz M A, Kumar S K, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014:cracking the glass ceiling of early death[J]. Blood, 2017,129(15):2111-2119.
[12] Karam C, Klein C J, Dispenzieri A, et al. Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome[J]. Neurology, 2015,84(19):1981-1987.
[13] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组, 中国抗淋巴瘤联盟. 淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志,2016,37(9):729-734.
[14] Treon S P, Xu L, Yang G, et al. MYD88 L265P somatic mutation in waldenstrom's macroglobulinemia[J]. N Engl J Med, 2012,367(9):826-833.
[15] Treon S P. How I treat Waldenstrom macroglobulinemia[J]. Blood, 2015,126(6):721-732.
[16] Campagnolo M, Zambello R, Nobile-Orazio E, et al. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy[J]. J Neurol Neurosurg Psychiatry, 2017,88(12):1094-1097.
[17] Treon S P, Tripsas C K, Meid K, et al. Ibrutinib in previously treated waldenstrom's macroglobulinemia[J]. New Engl J Med, 2015,372(15):1430-1440.
[18] 曹欣欣, 孟琦, 蔡昊,等. 华氏巨球蛋白血症患者的临床特征、myd88l265p、cxcr4whim突变和预后:单中心93例回顾性分析[J]. 中华血液学杂志, 2017(6):494-498.
[19] Attarian S, Boucraut J, Hubert A M, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies:response to IVIg therapy[J]. J Neurol Neurosurg Psychiatry, 2010,81(1):61-64.
[20] Delmont E, Jeandel P Y, Hubert A M, et al. Successful treatment with rituximab of one patient with CANOMAD neuropathy[J]. J Neurol, 2010,257(4):655-657.
[21] Garcia-Santibanez R, Zaidman C M, Sommerville R B, et al. CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA)[J]. J Neurol, 2018,[Epub ahead of print]
[22] Mauermann M L, Sorenson E J, Dispenzieri A, et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP[J]. J Neurol Neurosurg Psychiatry, 2012,83(5):480-486.
[23] Nasu S, Misawa S, Sekiguchi Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy[J]. J Neurol Neurosurg Psychiatry, 2012,83(5):476-479.
[24] Dispenzieri A. POEMS syndrome:2017 Update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2017,92(8):814-829.
[25] 中国医师协会血液科医师分会多发性骨髓瘤专业委员会. 多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)[J]. 中华内科杂志,2015,54(9):821-824
[26] Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017,28(suppl4):iv52-iv61.
[27] Dimopoulos M A, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR):an interim overall survival analysis of an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2017,18(10):1327-1337.
[28] Dimopoulos M, Wang M, Maisnar V, et al. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase Ⅲ ASPIRE study[J]. J Hematol Oncol, 2018,11(1):49.
[29] Oke O, Sethi T, Goodman S, et al. Outcomes from autologous hematopoietic cell transplantation versus chemotherapy alone for the management of light chain amyloidosis[J]. Biol Blood Marrow Transplant, 2017,23(9):1473-1477.
[30] Cohen A D. A phase i dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) amyloidosis[J]. Blood, 2014,124(21):4741.

Monoclonal protein and peripheral neuropathy

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Lu Bingyan, Dong Jinglian. Relationship of C-peptide levels and neuropathy in type 2 diabetes mellitus [J]. Journal of Capital Medical University, 2018, 39(1): 133-137.
[2]	Lu Bin, Duan Jinping, Meng Yan, Wu Xiaojuan, Yan Qian, Zhuang Xiaoming, Liu Bo. Impaired glucose regulation and hearing impairment [J]. Journal of Capital Medical University, 2015, 36(1): 98-102.
[3]	Lu Meihua;Sun Li. Clinical Study of Treatment for Diabetic Peripheral Neuropathy with Combination of Pentoxifylline and Microbalamin [J]. Journal of Capital Medical University, 2007, 28(1): 110-112.
[4]	Zhao Xiaoling;Wang Xianling;Xing Huafang. Clinical and Electrophysiological Study of Myotonic Dystrophy [J]. Journal of Capital Medical University, 2002, 23(4): 336-338.